Rigel Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Rigel Pharmaceuticals

04/08/2026 22:01

Rigel Pharmaceuticals Inc RIGL.OQ reported quarterly adjusted earnings of 88 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $3.28.  The mean expectation of five analysts for the quarter was for earnings of 62 cents per share. 
Revenue fell 22.6% to $78.70 million from a year ago; analysts expected $69.46 million. 
Rigel Pharmaceuticals Inc's reported EPS for the quarter was 88 cents​.
The company reported quarterly net income of $17.29 million.
Rigel Pharmaceuticals Inc shares had fallen by 4.3% this quarter and lost 12.6% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 40.4% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Rigel Pharmaceuticals Inc is $55.00, about 31.9% above its last closing price of $37.43
This summary was machine generated from LSEG data August 4 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.62
0.88
Beat
Mar. 31 2026 
0.76
0.44
Missed
Dec. 31 2025 
1.25
1.15
Missed
Sep. 30 2025 
0.85
1.46
Beat